STAT Inhibitors in Cancer

This volume, which includes contributions from leading scientists and clinicians in the field, provides definitive, state-of-the-art information on STAT inhibitors in a biological and clinical context. It gives an overview of the biology of the STAT family of transcription factors and their role in...

Full description

Bibliographic Details
Other Authors: Ward, Alister C. (Editor)
Format: eBook
Language:English
Published: Cham Humana 2016, 2016
Edition:1st ed. 2016
Series:Cancer Drug Discovery and Development
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 01807nmm a2200289 u 4500
001 EB001266134
003 EBX01000000000000000880718
005 00000000000000.0
007 cr|||||||||||||||||||||
008 161103 ||| eng
020 |a 9783319429496 
100 1 |a Ward, Alister C.  |e [editor] 
245 0 0 |a STAT Inhibitors in Cancer  |h Elektronische Ressource  |c edited by Alister C. Ward 
250 |a 1st ed. 2016 
260 |a Cham  |b Humana  |c 2016, 2016 
300 |a VII, 195 p. 11 illus. in color  |b online resource 
505 0 |a STATs in Health and Disease -- STAT Proteins in Cancer -- Translating STAT Inhibitors from the Lab to the Clinic -- Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials -- STAT3 Inhibitors in Cancer: A Comprehensive Update -- Targeting Upstream Janus Kinases -- Inhibitors of Upstream Inducers of STAT Activation 
653 |a Cancer 
653 |a Cancer Biology 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
490 0 |a Cancer Drug Discovery and Development 
028 5 0 |a 10.1007/978-3-319-42949-6 
856 4 0 |u https://doi.org/10.1007/978-3-319-42949-6?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616.994 
082 0 |a 571.978 
520 |a This volume, which includes contributions from leading scientists and clinicians in the field, provides definitive, state-of-the-art information on STAT inhibitors in a biological and clinical context. It gives an overview of the biology of the STAT family of transcription factors and their role in cancer etiology. Additionally, it describes the raft of therapeutic approaches being used to inhibit STATs in the context of various cancers, covering the full spectrum of therapeutic approaches to inhibiting STATs, and presenting emerging data from clinical trials